Zenabis Global has closed its previously announced rights offering. "The Rights Offering was over-subscribed and will result in the issuance of the maximum of 139,086,624 common shares of the Company (“Common Shares”) at a price of $0.15 per Common Share for gross proceeds of approximately $20.8 million," the team with the company explains.
"Zenabis is working with its transfer agent to calculate the amounts exercised under the basic subscription privilege and the additional subscription privilege in connection with the Rights Offering and will provide further details, including information required by National Instrument 45-106 – Prospectus Exemptions, once available," they conclude.
For more information:
Zenabis
info@zenabis.com
zenabis.com